The third annual Pharma Reputation Index, commissioned by the Association of the British Pharmaceutical Industry (ABPI), has found that the public looks favourably on the industry and continues to recognise its commitment to developing new medicines.
A High Court judgment on a judicial review brought by the British Generic Manufacturers Association (BGMA) has dismissed the organisation’s claim that it was unfairly excluded from talks on the next Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).
Figures from the ninth annual life sciences competitiveness indicators (LSCIs) report show that in 2022 the UK saw a substantial drop in foreign investment in its life sciences, compared to 2021. It fell to £1 billion from £1.9 billion, a drop of 47%. This saw the UK move down to ninth out of 18 comparator countries in 2021, from second place in 2021.
A report by the Association of the British Pharmaceutical Industry (ABPI) shows an ongoing need for AI, digital and data talent to support innovative drug discovery and development. The report, ‘Evolution of an innovation-based biopharmaceutical industry’, published on 8 June 2023, is updated every two years and investigates the latest trends and skills requirements for the life sciences industry in the UK.
We are excited to report that PharmaMedic's Managing Director, Dr Malcolm Barratt-Johnson has received a Global Fellow in Medicines Development (GFMD) award from the respected GMDP Academy.
Discussions are beginning on the next iteration of the UK’s voluntary scheme for branded medicines, pricing and access (VPAS) and the Association of the British Pharmaceutical Industry (ABPI) has set out its stall to government. It has published a four-point proposal for a Voluntary Scheme for Pricing, Access and Growth (VPAG), designed to reignite competitiveness and boost innovation in the life sciences sector, thereby improving health outcomes and the wider economy.
The 2023 annual conference of the UK’s Association of the British Pharmaceutical Industry (ABPI) at the end of April had a theme of Growing the UK as a Global Hub for Life Sciences.
Despite opposition from the Association of the British Pharmaceutical Industry (ABPI), the UK government has confirmed its plans to raise the revenue clawback rate paid by pharma for branded medicines under the statutory scheme by just over 3%, from 24.4% to 27.5% for 2023.
In 2023 manufacturers of branded medicines will be required to return almost £3.3bn in sales revenue to the government under the 2019 Voluntary scheme for branded medicines, pricing and access (VPAS), according to the Association of the British Pharmaceutical Industry (ABPI).
ABPI report warns UK is losing its global standing in clinical trials. The research ‘Rescuing Patient Access to Industry Clinical Trials in the UK’ shows that the number of industry clinical trials initiated in the UK per year fell by 41% between 2017 and 2021, with cancer trials falling by the same margin.
